Microneedle Sensor Assembly for Low-Pain Continuous Glucose Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional continuous glucose monitoring (CGM) devices suffer from tissue trauma, pain during insertion, limited accuracy, and signal latency due to the time required for glucose analyte to diffuse from capillary sources to the sensor, failing to timely detect hyperglycemia or hypoglycemia conditions.
Innovation Solution
A microneedle array-based analyte monitoring device with a shallower insertion depth into the dermal region, utilizing an energy harvesting module for power, and a controller to determine power-on events, enabling quick transition to operational modes for accurate and pain-free glucose monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional CGM devices use deeper insertion to access subcutaneous interstitial fluid, then continuous glucose monitoring is achieved, but tissue trauma and insertion pain increase
Solution Approach 1:
The device segments the insertion function into multiple microneedles (array configuration) that penetrate only the epidermis, rather than using a single deep-inserting needle. This segmentation allows access to interstitial fluid near capillaries in the dermal region without causing significant tissue trauma, as each microneedle is small and the overall insertion is less invasive
Solution Approach 2:
The device targets a specific local region (dermal region near capillary sources) rather than deep subcutaneous tissue. By positioning sensors in the dermal region where capillaries are accessible, the device achieves glucose monitoring accuracy while minimizing insertion depth and associated pain
2Measurement precision
If conventional CGM devices insert sensors deeper into subcutaneous tissue, then glucose monitoring capability is improved, but signal latency increases due to longer diffusion time
Solution Approach 1:
The device positions sensors in advance near capillary sources in the dermal region, where glucose analyte is already present in high concentration. This preliminary positioning eliminates the need for long diffusion paths, allowing rapid detection of glucose changes as they occur in the blood capillaries
Solution Approach 2:
The device uses interstitial fluid in the dermal region as an intermediary medium between blood capillaries and the sensor. This intermediary is in close proximity to capillary sources, allowing rapid exchange of glucose analyte and minimizing diffusion time compared to deeper subcutaneous positioning
3Loss of time
If microneedle array is inserted into dermal region for rapid glucose detection, then signal latency is reduced, but insertion complexity increases
Solution Approach 1:
The microneedle array is designed to be self-inserting or easily insertable into the dermal region without requiring complex insertion mechanisms. The microneedles' small size and array configuration allow them to penetrate the skin barrier with minimal force, and the device automatically positions itself once inserted, eliminating the need for complex control systems
Data Source
AI summary
Aspects of the current subject matter are directed to a sensor assembly of an analyte monitoring device including one or more microneedle arrays. Aspects are directed to components and architecture of a sensor assembly to implement power and processing aspects of a microneedle array-based continuous analyte monitoring device for the detection and measuring of an analyte. A source of a power-on event is determined, and the analyte monitoring device is transitioned to a mode that corresponds to the determined source. When a power-on event is determined to be a valid power-on event, the analyte monitoring device is transition to a mode that corresponds to a type of the valid power-on event.